FDA Approves Antibiotic Avycaz For Treating Complicated Infections

The Food and Drug Administration Feb. 25 approved Actavis Plc’s antibiotic Avycaz (ceftazidime-avibactam).

Avycaz is approved to treat adults with complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI), including kidney infections, who have limited or no treatment options, the agency said. The product is a fixed-combination drug containing ceftazidime, a previously approved cephalosporin antibacterial drug, and avibactam, a new beta-lactamase inhibitor.

“The FDA is committed to making therapies available to treat patients with unmet medical need,” said Edward Cox, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and ...